Insiders who reported open-market trades in the last 12 months at the companies Claire Mazumdar files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Claire Mazumdar is a corporate insider, tracked as Chief Executive Officer, Director of Bicara Therapeutics Inc. (BCAX). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Claire Mazumdar submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Claire Mazumdar been buying or selling stock?
Recorded transactions: 0 open-market purchases and 17 open-market sales ($4.06M) across all tracked filings.
Claire Mazumdar is Chief Executive Officer, Director of Bicara Therapeutics Inc. (BCAX). 12 SEC Form 4 filings on record going back to 2025, most recently on 12 August 2026. Most recent open-market trade: sold $280K of BCAX on 12 August 2026. Lifetime open-market sales: $4.06M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Claire Mazumdar.
InsiderAlpha's records for Claire Mazumdar go back to 2025: 12 primary Form 4 filings, an average of 6.0 per year. 53 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
